Por favor, use este identificador para citar o enlazar este ítem:
https://hdl.handle.net/10495/25207
Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Rojas Camargo, John Jairo | - |
dc.contributor.author | Aristizábal, Julián | - |
dc.contributor.author | Sánchez, Joan | - |
dc.date.accessioned | 2022-01-08T16:28:25Z | - |
dc.date.available | 2022-01-08T16:28:25Z | - |
dc.date.issued | 2013 | - |
dc.identifier.uri | http://hdl.handle.net/10495/25207 | - |
dc.description.abstract | ABSTRACT: Verapamil hydrochloride is a drug used to treat arrhythmias. In this study, a D-optimal mixture design with 16 runs was used to select the best combination of three polymers into a matrix that rendered an 8 h in vitro release profile of verapamil. hydrochloride (HCl) which fulfill a once-a-day modified release in compliance with the United States Pharmacopeia (USP) specifications. The Korsmeyer-Peppas model was used to fit the dissolution data since it presented the best fitting characteristics. A cubic model predicted the best formulation of verapamil.HCl containing carnauba wax, hydroxypropyl methyl cellulose and Avicel_PH101 at the 40, 20 and 40% levels, respectively. Validation runs confirmed the accuracy of the cubic models which include these three components. | spa |
dc.format.extent | 7 | spa |
dc.format.mimetype | application/pdf | spa |
dc.language.iso | eng | spa |
dc.publisher | Academic Journals | spa |
dc.type.hasversion | info:eu-repo/semantics/publishedVersion | spa |
dc.rights | info:eu-repo/semantics/openAccess | spa |
dc.rights.uri | http://creativecommons.org/licenses/by/2.5/co/ | * |
dc.title | Assessment of a modified release verapamil.HCl matrix compacts : Effect of formulation composition on the in-vitro release kinetic | spa |
dc.type | info:eu-repo/semantics/article | spa |
dc.publisher.group | Diseño y Formulación de Medicamentos Cosméticos y Afines | spa |
dc.identifier.doi | 10.5897/AJPP2013.3466 | - |
oaire.version | http://purl.org/coar/version/c_970fb48d4fbd8a85 | spa |
dc.rights.accessrights | http://purl.org/coar/access_right/c_abf2 | spa |
dc.identifier.eissn | 1996-0816 | - |
oaire.citationtitle | African Journal of Pharmacy and Pharmacology | spa |
oaire.citationstartpage | 793 | spa |
oaire.citationendpage | 800 | spa |
oaire.citationvolume | 7 | spa |
oaire.citationissue | 15 | spa |
dc.rights.creativecommons | https://creativecommons.org/licenses/by/4.0/ | spa |
dc.publisher.place | Lagos, Nigeria | spa |
dc.type.coar | http://purl.org/coar/resource_type/c_2df8fbb1 | spa |
dc.type.redcol | https://purl.org/redcol/resource_type/ART | spa |
dc.type.local | Artículo de investigación | spa |
dc.subject.decs | Verapamilo | - |
dc.subject.decs | Verapamil | - |
dc.subject.decs | Dinámicas no Lineales | - |
dc.subject.decs | Nonlinear Dynamics | - |
dc.subject.lemb | Diseño experimental | - |
dc.subject.lemb | Experimental design | - |
dc.subject.proposal | Controlled-release preparations | spa |
dc.description.researchgroupid | COL0003623 | spa |
dc.relation.ispartofjournalabbrev | Afr. J. Pharm. Pharmacol. | spa |
Aparece en las colecciones: | Artículos de Revista en Farmacéutica y Alimentarias |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
RojasJohn_2013_AssessmentModifiedVerapamil.pdf | Artículo de investigación | 521.62 kB | Adobe PDF | Visualizar/Abrir |
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons